Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alterity TherapeuticsASX:ATH -0.99%28 Cash-to-Debt is 193.36 as of Jun. 2026, which is 32% below its 10-year median of 282.74. GuruFocus rates ASX:ATH with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,393 Biotechnology companies, Alterity Therapeutics ranks better than 80.9% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Alterity Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 193.36.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Alterity Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Alterity Therapeutics's Cash-to-Debt or its related term are showing as below:
ASX:ATH'
s Cash-to-Debt Range Over the Past 10 Years
Min: 75.11 Med: 282.74 Max: No Debt
Current: 193.36
During the past 13 years, Alterity Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 75.11. And the median was 282.74.
ASX:ATH's Cash-to-Debt is ranked better than 80.9% of 1393
companies
in the Biotechnology industry
Industry Median: 6.78
vs ASX:ATH: 193.36
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Alterity Therapeutics Cash-to-Debt Related Terms
Alterity Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Alterity Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASX:ATH vs VRTX, REGN, MRNA: Cash-to-Debt Comparison
For the Biotechnology subindustry, Alterity Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alterity Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Alterity Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alterity Therapeutics (ASX:ATH) has a Cash-to-Debt of 193.36 as of Jun. 2026. This is 32% below median its historical median of 282.74. Over the past decade, Alterity Therapeutics' Cash-to-Debt has ranged from 75.11 to 10,000.00. According to the industry distribution chart, Alterity Therapeutics ranks #266 out of 1393 companies in the Biotechnology industry, placing it in the top 19.1%.
Is Alterity Therapeutics' Cash-to-Debt too high?
Alterity Therapeutics' current Cash-to-Debt of 193.36 is 32% below median its 10-year median of 282.74. Over the past 10 years, this metric has ranged from a low of 75.11 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.78. Alterity Therapeutics' value of 193.36 is 2751.9% above this industry median. Based on the distribution chart, Alterity Therapeutics ranks #266 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alterity Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alterity Therapeutics ranks #266 out of 1393 companies for Cash-to-Debt. This places Alterity Therapeutics in the top 19% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 6.78. Alterity Therapeutics' value of 193.36 is 2751.9% above this benchmark. Historically, Alterity Therapeutics' own Cash-to-Debt has ranged from 75.11 to 10,000.00 over the past decade. While the company's 10-year median is 282.74 vs. the industry median of 6.78, Alterity Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.78, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alterity Therapeutics's current Cash-to-Debt of 193.36 is 2751.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alterity Therapeutics's current Cash-to-Debt is 193.36, which is 32% below median its own 10-year median of 282.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current Cash-to-Debt of 193.36. The current Cash-to-Debt is 193.36, which is 32% below median its 10-year median of 282.74 and 2751.9% above the Biotechnology industry median of 6.78. Alterity Therapeutics' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current Cash-to-Debt is 193.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
28GF Score
Get the complete analysis for ASX:ATH
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ATH has been successfully added to your 
